The Identification of Novel Prognostic Markers in Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Prognostic Markers in Renal Cancer

NCT01002937

Renal Cell Carcinoma

COMPLETED

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

NCT02105168

Melanoma Non Small Cell Lung Cancer Small Cell Lung Cancer

UNKNOWN NA

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

NCT00974610

Breast Cancer Colorectal Cancer Lung Cancer +2 more

COMPLETED

Identification and Characterization of Molecular Markers in Musculoskeletal Tumors

NCT02199938

Soft Tissue and Bone Tumors Sarcoma Sarcoma of Bone +1 more

TERMINATED

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

NCT00991991

Melanoma (Skin)

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new drugs for routine cancer therapy; offering the potential of selecting those patients with tumour types most likely to benefit from therapy. Furthermore, new insights into disease biology may be gained.

Main research question/ objective - Are there features of primary melanoma or lymph node metastases that predict subsequent clinical outcome better than existing markers?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malignant melanoma tumour tissue

No interventions assigned to this group

Benign pigmented lesions & other skin cancers

Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of melanoma
* Adequate paraffin-embedded material available for analysis.
* Adequate clinical follow-up information
* Written informed consent where applicable